Sector News

Shake-up at AstraZeneca as two immuno-oncology leaders leave

January 6, 2015
Life sciences
(Reuters) – AstraZeneca has appointed a new leader for its all-important immuno-oncology drug development operation after the departure of the previous head for personal reasons, the British-based drugmaker said on Monday.
 
Rachel Humphrey left the company at the end November and was replaced last month by Robert Iannone, a member of the global medicines development team, a spokeswoman said in response to inquiries. Her departure was not announced at the time.
 
Humphrey’s exit coincides with the loss of another leader in immuno-oncology, albeit from a different part of the firm. Peter Emtage, who was involved in early research at AstraZeneca’s unit MedImmune, was appointed to a senior position at biotech company Intrexon on Dec. 4.
 
AstraZeneca said the two departures were a coincidence and the company’s work in immuno-oncology was proceeding at full steam, with no problems with any programmes. “It’s business as usual,” the spokeswoman said.
 
The drugmaker, which saw off a $118 billion takeover attempt by Pfizer last year, is banking on new cancer medicines to help revive its fortunes.
 
It is also hoping for an imminent boost to its heart drug Brilinta from results of a clinical trial – known as PEGASUS – assessing the medicine’s use in patients who experienced a heart attack 1-3 years ago. That group could more than double the number of patients eligible for Brilinta. (Reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach